EUVIMEDEUVIMED entdecken
Open Access

Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors

Bin Tan iD, Xueying Liang, Ahmadullah Ansari, Prakash Jadhav, Haozhou Tan, Kan Li, Francesc Xavier Ruiz iD, Eddy Arnold iD, Xufang Deng, Jun Wang iD

Journal of Medicinal Chemistry · 28.11.2024 · 67 (22) · 20399-20420

DOI: 10.1021/acs.jmedchem.4c01872 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.11.2024. Verfasst von Bin Tan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United…. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Drug Design. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic is caused by SARS-CoV-2, a highly transmissible and pathogenic RNA betacoronavirus. Like other RNA viruses, SARS-CoV-2 continues to evolve with or without drug selection pressure, and many variants have emerged since the beginning of the pandemic. The papain-like protease, PLpro, is a cysteine protease that cleaves viral polyproteins as well as ubiquitin and ISG15 modifications from host proteins. Leveraging our recently discovered Val70Ub binding site in PLpro, we designed covalent PLpro inhibitors by connecting cysteine reactive warheads to the biarylphenyl PLpro inhibitors via flexible linkers. Several leads displayed potent enzymatic inhibition (IC50 = 0.1-0.3 μM) and antiviral activity (EC50 = 0.09-0.96 μM). Fumaramide inhibitors Jun13567 (15), Jun13728 (16), and Jun13714 (18) showed favorable in vivo pharmacokinetic properties with intraperitoneal injection. The X-ray crystal structure of PLpro with Jun13567 (15) validated our design strategy, revealing covalent conjugation between the catalytic Cys111 and the fumaramide warhead. The results suggest these covalent PLpro inhibitors are promising SARS-CoV-2 antiviral drug candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsDrug DesignAnimalsHumansCoronavirus Papain-Like ProteasesStructure-Activity RelationshipCOVID-19 Drug TreatmentRatsCoronavirus 3C ProteasesProtease InhibitorsCysteine Proteinase InhibitorsCrystallography, X-RayBinding SitesModels, Molecular

Substanzen

Antiviral AgentsCoronavirus Papain-Like Proteasespapain-like protease, SARS-CoV-2Coronavirus 3C ProteasesProtease InhibitorsCysteine Proteinase Inhibitors

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.
  • Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma 74078, United States.
  • Center for Advanced Biotechnology and Medicine, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.
  • Department of Chemistry and Chemical Biology, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.
  • Oklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, Oklahoma 74078, United States.

ORCID-Profile: Bin Tan, Francesc Xavier Ruiz, Eddy Arnold, Jun Wang

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Tan, B., Liang, X., Ansari, A., Jadhav, P., Tan, H., Li, K., Ruiz, F. X., Arnold, E., Deng, X., & Wang, J. (2024). Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors. Journal of Medicinal Chemistry, 67(22), 20399-20420. https://doi.org/10.1021/acs.jmedchem.4c01872

Vancouver

Tan B, Liang X, Ansari A, Jadhav P, Tan H, Li K, et al. Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors. Journal of Medicinal Chemistry. 2024;67(22):20399-20420. doi:10.1021/acs.jmedchem.4c01872

BibTeX
@article{Tan2024,
  author = {Tan, Bin and Liang, Xueying and Ansari, Ahmadullah and Jadhav, Prakash and Tan, Haozhou and Li, Kan and Ruiz, Francesc Xavier and Arnold, Eddy and Deng, Xufang and Wang, Jun},
  title = {Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {22},
  pages = {20399--20420},
  doi = {10.1021/acs.jmedchem.4c01872}
}
Kostenlos starten →